ClinicalTrials.gg
CompletedNCT06856291TRIM-IRUpdated Oct 2, 2026

Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance

An observational study in Obesity and Obesity-related Medical Conditions, Obesity and Overweight and Insulin Sensitivity/Resistance, sponsored by ETH Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by ETH Zurich · Observational

How we know · 3 judgments

Updated Oct 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Obesity with a site in Switzerland — 22 open to participants now, 30 under way, 5 of them phase 3. Obesity · Switzerland.

Enrollment
25th of 37
40 · median 85
Started
2025
with 8 others
Observational
37 of 127
9 open now
Registered
115th of 127
by date

Among the 127 studies in Obesity with a site in Switzerland, this one is the 25th largest by enrollment of the 37 observational ones that give a count, is one of 9 that started in 2025, is one of 37 observational ones, and was the 115th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

22 of the 127 studies in Obesity with a site in Switzerland are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Obesity with a site in Switzerland, or all of them as a file.
02

Study summary

Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.

The TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.

The investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.

A total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.

03

Conditions studied

  • Obesity and Obesity-related Medical Conditions
  • Obesity and Overweight
  • Insulin Sensitivity/Resistance
  • Semaglutide

Keywords

  • Insulin Resistance
  • incretin mimetics
  • semaglutide
  • weight loss
  • adipose tissue function
  • obesity
  • hyperinsulinemic euglycemic clamp
  • obesity management
  • insulin sensitivity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators plan to include a total of 40 non-diabetic, obese individuals that will undergo treatment with semaglutide as a weight-loss intervention independent of our observational study. To avoid a highly heterogeneous participant group, inclusion in the study will be limited to individuals with a BMI between 30 and 40 kg/m². Patients with a prediabetic state will not be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 60 years
  2. 30 - 40 kg/m2

    a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg/m2

  3. Planned therapy with semaglutide as a weight loss intervention
  4. No known presence of a diabetic state
  5. Ability to understand and sign a Patient Information and Consent Form

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or active breast feeding

    1. Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established.
    2. Pregnancy is an exclusion criterion for the planned investigations to avoid placing pregnant individuals under unnecessary physical or psychological stress that could pose risks to both the individual and the fetus.
  2. Medication and/or pathologies that prevent the safe execution of the fat tissue (e.g. allergy towards local anesthetics, disorders of coagulation, treatment with anticoagulants)
  3. Medical conditions that prevent examinations and testing (e.g. epilepsia, symptomatic cardiovascular disease)
  4. History of or planned bariatric surgery
  5. ≥ 6.5% as measured by the central laboratory at screening
  6. Fasting plasma-glucose >7.0 mmol/l
  7. History of type 1 or type 2 diabetes mellitus
  8. Treatment with glucose-lowering agent(s) (e.g. Metformin) within 90 days before screening
  9. Treatment with a GLP-1 (glucagon like peptide 1) receptor agonist within 180 days before screening
  10. A self-reported change in body weight >5% within 90 days before screening
  11. Active (\<2a since remission)
  12. Treatment with any medication for the indication of obesity within the past 90 days before screening
  13. Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) > 10 mIU/L or \< 0.4 mIU/L as measured by the central laboratory at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Non-diabetic obese individuals on semaglutide for weight loss

    Non-diabetic obese individuals with planned semaglutide treatment as a weight loss intervention

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in body weight (%)

    Time frame: 16 weeks

Secondary outcomes

  1. Change in fat mass (%)

    measured by DEXA (dual energy x-ray absorptiometry)

    Time frame: 16 weeks

  2. Change in lean mass (%)

    measured by DEXA

    Time frame: 16 weeks

  3. Change in abdominal visceral fat area (in cm2)

    measured by DEXA

    Time frame: 16 weeks

Other outcomes

  1. Change in cell size of adipose tissue after 16 weeks of semaglutide treatment

    The size of adipocytes is a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations.

    Time frame: 16 weeks

  2. Changes in cell distribution of adipose tissue after 16 weeks of semaglutide treatment

    Changes in the distribution of adipocytes and other components of adipose tissue (e.g. macrophages, progenitors) serve as a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations.

    Time frame: 16 weeks

  3. Changes in signs of fibrosis in adipose tissue after 16 weeks of semaglutide treatment

    Signs of fibrosis are a direct measure of adipose tissue quality and function. They will be evaluated through histopathological analysis.

    Time frame: 16 weeks

  4. Changes in inflammatory activity of adipose tissue after 16 weeks of semaglutide treatment

    Inflammatory activity, measured by the number and type of white blood cells infiltrating adipose tissue, is a direct way to assess adipose tissue quality and function. It will be evaluated by quantifying inflammatory cells within the tissue.

    Time frame: 16 weeks

  5. Change in adipokine secretion pattern after 16 weeks of semaglutide treatment

    The adipokine-secretion pattern is an indirect way to assess adipose tissue quality and function. We will analyze leptin, adipokines, and other relevant markers in blood samples and potentially in adipose tissue from strong or weak responders to identify patterns that may help predict significant changes or the absence of response.

    Time frame: 16 weeks

  6. Change in systemic inflammation after 16 weeks of semaglutide treatment

    Adipose tissue dysfunction can contribute to systemic inflammation, making it an indirect measure of adipose tissue quality. Serum levels of systemic inflammatory markers such as C-reactive protein (CRP), interleukins, and tumor necrosis factor-alpha (TNF-α) will be assessed before and after 16 weeks of semaglutide treatment.

    Time frame: 16 weeks

07

Study locations

1 site
  • Cantonal Hospital Aarau
    Aarau, Canton of Aargau 5001, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2026, 17 months.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 17 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 4, 2025
StartActual
Mar 15, 2025
Primary completionActual
Sep 6, 2026was Aug 2026
CompletionActual
Sep 6, 2026was Aug 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Sites
1 site added, 1 site removed
Show site
  • Cantonal Hospital Aarau · Aarau, Switzerland
Show 1 removed
  • Cantonal Hospital Aarau · Aarau, Switzerland
Oct 2, 2026
Primary completion
Aug 31, 2026→Sep 6, 2026 (actual)
Oct 2, 2026
Study completion
Aug 31, 2026→Sep 6, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Cantonal Hospital Aarau · Aarau, Switzerland
    Show 1 removed
    • Cantonal Hospital Aarau · Aarau, Switzerland
    Primary completion Aug 31, 2026→Sep 6, 2026 (now actual)
    Study completion Aug 31, 2026→Sep 6, 2026 (now actual)
    + 4 other changes: index terms, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06856291
Lead sponsor
ETH Zurich
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 15, 2025
Primary completion
Sep 6, 2026
Completion
Sep 6, 2026
Last update
Oct 2, 2026

Study contacts

Christian Wolfrum, Prof. Dr.
study chair · ETH Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion